TY -的A2全Dae-Geun盟——Mandell乔纳森•b . AU - Lu Feiqi AU -费斯,马修盟——他,Jan h . AU -郭Jianxia盟——继续萎缩,丽贝卡·j . AU -韦斯科特·r . PY - 2019 DA - 2019/07/11 TI -联合治疗戒酒硫、铜、和阿霉素对骨肉瘤:在体外支持一种新型药物再利用策略SP - 1320201六世- 2019 AB -尽管许多癌细胞有明显高于铜浓度与正常细胞和组织相比,铜的作用在癌症生物学和转移性疾病仍知之甚少。在这里,我们研究了铜在骨肉瘤的重要性,经常转移到肺部和往往是chemoresistant。K12和K7M2鼠OS细胞不同转移表型:K7M2高度转移,而K12的所以要少得多。使用原子吸收测定细胞内铜水平。铜转运蛋白被qPCR量化。阿霉素的细胞毒性、戒酒硫和氯化铜(II)与细胞荧光染色可行性评估。此外,K7M2活细胞计数测定台盼蓝排斥染色后72小时的治疗。发现铜含量明显高于K12的OS细胞比K7M2细胞。qPCR表明K12的细胞移植铜泵CTR1涌入以及表达下调铜相比,射流泵ATP7A K7M2 OS细胞。联合治疗的氯化铜(50 nM)与戒酒硫(80海里)只有K12的细胞的细胞毒性。 Triple treatment with doxorubicin, disulfiram, and copper displayed potent and durable cytotoxicity of highly metastatic K7M2 cells. We demonstrate here that murine OS cell lines differing in metastatic potential also vary in endogenous copper levels and regulation. Additionally, these differences in copper regulation may contribute to selective cytotoxicity of K12 cells by extremely low doses of copper-potentiated disulfiram. The combination of doxorubicin, disulfiram, and copper should be explored as a therapeutic strategy against OS metastases. SN - 1357-714X UR - https://doi.org/10.1155/2019/1320201 DO - 10.1155/2019/1320201 JF - Sarcoma PB - Hindawi KW - ER -